Expression of B7-2 (CD86) molecules by Reed-Sternberg cells of Hodgkin's disease

Leukemia

Volumn 11, Issue 6, 1997, Pages 846-851

  Van Gool, S W ^a,c   Delabie, J ^c   Vandenberghe, P ^b   Coorevits, L ^a   De Wolf Peeters, C ^c   Ceuppens, J L ^a,d  

^a Laboratory of Experimental Neurology   (Belgium)

^b Lab of Experimental Hematology   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d Faculty of Medicine   (Belgium)

Author keywords

CD80; CD86; Hodgkin's disease; Non Hodgkin's lymphomas; Tumor immunology

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; CYTOKINE; MONOCLONAL ANTIBODY;

ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; HELPER CELL; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPH NODE; LYMPHOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REED STERNBERG CELL; SYMPTOMATOLOGY; T CELL LYMPHOMA; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR REJECTION;

EID: 0030925884     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400683     Document Type: Article

References (28)

1. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14: 233-258.
2. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992; 356: 607-609.
3. + T cells by B7-transfected melanoma cells. Science 1993; 259: 368-370.
4. Chen L, Ashe S, Brady WA, Hellström I, Hellström KE, Ledbetter JA, McGowan P, Linsley PS. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71: 1093-1102.
5. Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler L, Freeman G, Glimcher L. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci USA 1993; 90: 5687-5690.
6. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellström I, Hellström KE. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994; 179: 523-532.
7. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol 1994; 153: 421-428.
8. Baskar S, Glimcher L, Nabavi N, Jones RT, Ostrand-Rosenberg S. Major histocompatibility complex class II + B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 1995; 181: 619-629.
9. Dunussi-Joannopoulos K, Weinstein HJ, Nickerson PW, Strom TB, Burakoff SJ, Croop JM, Arceci RJ. Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood 1996; 87: 2938-2946.
10. Gajewski TF, Fallarino F, Uyttenhove C, Boon T. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J Immunol 1996; 156: 2909-2917.
11. Li YW, Hellström KE, Newby SA, Chen LP. Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors. J Exp Med 1996; 183: 639-644.
12. Matulonis U, Dosiou C, Freeman G, Lamont C, Mauch P, Nadler LM, Griffin LD. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity: further evidence that B7-1 and B7-2 are functionally distinct. J Immunol 1996; 156: 1126-1131.
13. Baskar S, Clements VK, Glimcher LH, Nabavi N, Ostrand-Rosenberg S. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules. J Immunol 1996; 156: 3821-3827.
14. Delabie J, Ceuppens JL, Vandenberghe P, de Boer M, Coorevits L, De Wolf-Peeters C. The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines. Blood 1993; 82: 2845-2852.
15. de Boer M, Conroy L, Min HY, Kwekkeboom J. Generation of monoclonal antibodies to human lymphocyte cell surface antigens using insect cells expressing recombinant proteins. J Immunol Meth 1992; 152: 15-23.
16. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 577-580.
17. Kamesaki H, Fukuhara S, Tatsumi E, Uchino H, Yamabe H, Miwa H, Shirakawa S, Hatanaka M, Honjo T. Cytochemical, immunologic, chromosomal, and molecular genetic analysis of a novel cell line derived from Hodgkin's disease. Blood 1986; 68: 285-292.
18. Diehl V, Kirchner HH, Burrichter H, Stein H, Fonatsch C, Gerdes J, Schaadt M, Heit W, Uchanska-Ziegler B, Ziegler A, Heintz F, Sueno K. Characteristics of Hodgkin's disease-derived cell lines. Cancer Treat Rep 1982; 66: 615-632.
19. Van Gool SW, Ceuppens JL, Walter H, de Boer M. Synergy between cyclosporin A and a monoclonal antibody to B7 in blocking alloantigen-induced T-cell activation. Blood 1994; 83: 176-183.
20. Munro JM, Freedman AS, Aster JC, Gribben JG, Lee NC, Rhynhart KK, Banchereau J, Nadler LM. In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. Blood 1994; 83: 793-798.
21. Gruss HJ, Hirschstein D, Wright B, Ulrich D, Caligiuri MA, Barcos M, Strockbine L, Armitage RJ, Dower SK. Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease. Blood 1994; 84: 2305-2314.
22. Nozawa Y, Wachi E, Tominaga K, Abe M, Wakasa H. A novel monoclonal antibody (FUN-1) identifies an activation antigen in cells of the B-cell lineage and Reed-Sternberg cells. J Pathol 1993; 169: 309-315.
23. Fisher RI, Bostick-Bruton F, Sauder DN, Scala G, Diehl V. Neoplastic cells obtained from Hodgkin's disease are potent stimulators of human primary mixed lymphocyte cultures. J Immunol 1983; 130: 2666-2670.
24. Fisher RI, Cossman J, Diehl V, Volkman DJ. Antigen presentation by Hodgkin's disease cells. J Immunol 1985; 135: 3568-3571.
25. McKenzie JL, Egner W, Calder VL, Hart DN. Hodgkin's disease cell lines: a model for interleukin-1-independent accessory cell function. Immunology 1992; 77: 345-353.
26. Gruss H-J, Ulrich D, Braddy S, Armitage RJ, Dower SK. Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells, Eur J Immunol 1995; 25:2083-2089.
27. Delabie J, Vandenberghe E, Kennes C, Verhoef G, Foschini MP, Stul M, Cassiman JJ, De Wolf-Peeters C. Histiocyte-rich B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin's disease, paragranuloma subtype. Am J Surg Pathol 1992; 16: 37-48.
28. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734-1736.